Scientists at Gwangju Institute of Science & Technology and JD Bioscience Inc. have disclosed 5-HT2A receptor antagonists reported to be useful for the treatment of cancer, hyperlipidemia, obesity, diabetes, arteriosclerosis, hepatic steatosis, fibrosis and hypertension.

Fudan University has described dihydroorotate dehydrogenase (DHODH) inhibitors reported to be useful for the treatment of bone disorders, immunological disorders, inflammatory disorders, viral infections and cancer.

Shanghai Yidi Biotechnology Co. Ltd. has divulged glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes.

Repare Therapeutics Inc. has identified prodrugs acting as DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Harvard College has published compounds reported to be useful for the treatment of SARS-CoV-2 infections (COVID-19).

Rezubio Pharmaceuticals Co. Ltd. has disclosed drug conjugates comprising somatostatin receptor type 5 (SSTR5) antagonists covalently linked to a hydrophilic moiety through a linker reported to be useful for the treatment of type 2 diabetes.

Quantx Biosciences US Inc. has synthesized DNA polymerase θ (POLQ) inhibitors reported to be useful for the treatment of cancer.

Suzhou Puhe Biopharma Co. Ltd. has described apelin receptor (APLNR) agonists reported to be useful for the treatment of idiopathic pulmonary fibrosis, diabetes, obesity, heart failure, hypertension, pulmonary hypertension, sarcopenia and scleroderma.

Evotec International GmbH has divulged NLRP3 inflammasome modulators reported to be useful for the treatment of asthma, rheumatoid arthritis, gout, Crohn’s disease, hypertension, ulcerative colitis, metabolic and neurological disorders, among others.